Glioblastoma Breakthrough: Molecule Blocks Key Tumor Gene & Shows Promise

Glioblastoma Research: New Molecule Shows Promise in Blocking Tumor Growth

Glioblastoma, a particularly aggressive form of brain cancer, remains a significant challenge for medical professionals. In France alone, approximately 3,500 new cases are diagnosed each year and despite treatment, the vast majority of patients experience relapse, with a dismal 5-year survival rate of only 5%. However, recent research offers a glimmer of hope. Scientists have identified a molecule capable of blocking AVIL, a key gene driving the growth and spread of glioblastoma cells.

Researchers at the UVA Comprehensive Cancer Center have discovered a molecule that targets AVIL, a gene encoding a protein essential for glioblastoma cell survival. This discovery, published in Science Translational Medicine, represents a potentially significant step forward in the fight against this devastating disease. “The novelty lies in the fact that we are targeting a protein essential to glioblastoma cells, using a small molecule with proven in vivo activity,” explains Hui Li, a researcher involved in the study. “To our knowledge, this pathway has never been exploited for therapeutic purposes.”

The initial discovery, made in 2020, demonstrated that blocking the activity of the AVIL gene could completely eliminate glioblastoma cells in laboratory settings without harming healthy cells. However, the techniques used at that time were not suitable for human application. For the past five years, researchers have been diligently testing various compounds and molecules to identify one capable of effectively neutralizing the harmful effects of the AVIL gene.

Targeting a Fundamental Vulnerability

The identified molecule not only targets tumor cells while sparing healthy brain tissue but also possesses the crucial ability to cross the blood-brain barrier – a significant hurdle for many potential neurological treatments. Researchers believe that, in humans, this molecule could potentially be administered orally, offering a less invasive treatment option. However, further research is necessary before clinical trials can begin.

The difficulty in treating glioblastoma stems from its inherent resistance to conventional therapies. As explained in research funded by the National Brain Tumor Society (NBTS), glioblastoma tumors are adept at blocking the natural process of cell death, known as apoptosis. This “self-destruct” mechanism, normally triggered by treatments like radiation and chemotherapy, is effectively disabled in glioblastoma cells, allowing them to survive and proliferate even after aggressive intervention. The tumor essentially hijacks the body’s natural defenses, turning them into tools for its own survival.

A clinical trial is underway, spurred by NBTS-funded research at UCLA, focusing on a different approach to overcome this resistance. The trial investigates an antibody-drug conjugate (ADC), ABBV-155, which showed promise in pre-clinical studies. This highlights the multifaceted approach being taken to combat glioblastoma.

The Need for New Targets

The search for new molecular targets is critical, as highlighted by research published in Inside Precision Medicine. Glioblastoma has a median survival of only 12–16 months from diagnosis, despite extensive treatments. Researchers note that therapeutic progress has been limited over the past 20 years due to an incomplete understanding of the tumor’s complex biology. The identification of the AVIL gene and the development of a molecule to block its activity represent a significant step towards addressing this knowledge gap.

Another avenue of research focuses on enzymes involved in tumor growth. Scientists have identified an enzyme target within the hexosamine synthesis pathway, which is often upregulated in cancer cells and plays a role in supporting rapid growth. While research into this pathway is ongoing, it offers another potential target for future glioblastoma treatments. Initial studies focused on GFAT1, a rate-limiting enzyme in this pathway, but researchers found that inhibiting it alone had limited effect on glioblastoma growth.

Gene Therapies and Future Directions

Beyond small molecule inhibitors and enzyme targets, gene therapies are also being explored. Research has identified a gene, MDA-9/Syntenin, that regulates protective autophagy in glioma stem cells, allowing them to resist programmed cell death. Blocking the expression of this gene can induce cancer cell death. Researchers have identified a gene that helps glioblastoma cells turn other cells cancerous, and targeting this gene in mouse models has slowed tumor growth and spread.

“Glioblastoma patients urgently need better treatment options,” emphasizes Hui Li. “Standard treatments have not fundamentally evolved for decades and the survival rate remains very low. Our goal is to bring an entirely new mechanism of action into the clinic, targeting a fundamental vulnerability in glioblastoma biology.” While the research on the AVIL-blocking molecule is still in its early stages, it offers a promising new avenue for the development of more effective glioblastoma therapies. Further research and clinical trials will be essential to determine its safety and efficacy in humans.

Personalized medicine and combination therapies are also showing promise in tackling treatment resistance, suggesting a future where glioblastoma treatment is tailored to the individual characteristics of each patient’s tumor.